vs
百利高（PRGO）与思佳讯（SWKS）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是思佳讯的1.2倍（$1.1B vs $943.7M），思佳讯净利率更高（3.8% vs -127.8%，领先131.6%），思佳讯同比增速更快（-1.0% vs -2.5%），过去两年思佳讯的营收复合增速更高（2.1% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
思佳讯是总部位于美国加利福尼亚州尔湾的半导体企业，公司股票在纳斯达克全球精选市场挂牌交易，股票代码为SWKS，同时也是标普500指数的成分股之一，在全球射频半导体领域拥有较高市场地位。
PRGO vs SWKS — 直观对比
营收规模更大
PRGO
是对方的1.2倍
$943.7M
营收增速更快
SWKS
高出1.5%
-2.5%
净利率更高
SWKS
高出131.6%
-127.8%
两年增速更快
SWKS
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $943.7M |
| 净利润 | $-1.4B | $35.6M |
| 毛利率 | 32.6% | 40.8% |
| 营业利润率 | -116.0% | 4.5% |
| 净利率 | -127.8% | 3.8% |
| 营收同比 | -2.5% | -1.0% |
| 净利润同比 | -3093.9% | -48.2% |
| 每股收益（稀释后） | $-10.23 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOSWKS
| Q2 26 | — | $943.7M | ||
| Q1 26 | — | $1.0B | ||
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.1B | $965.0M | ||
| Q1 25 | $1.0B | $953.2M | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $1.0B |
净利润PRGOSWKS
| Q2 26 | — | $35.6M | ||
| Q1 26 | — | $79.2M | ||
| Q4 25 | $-1.4B | $141.4M | ||
| Q3 25 | $7.5M | — | ||
| Q2 25 | $-8.4M | $105.0M | ||
| Q1 25 | $-6.4M | $68.7M | ||
| Q4 24 | $-44.4M | $162.0M | ||
| Q3 24 | $-21.0M | $60.5M |
毛利率PRGOSWKS
| Q2 26 | — | 40.8% | ||
| Q1 26 | — | 41.3% | ||
| Q4 25 | 32.6% | 40.7% | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | 41.6% | ||
| Q1 25 | 37.6% | 41.1% | ||
| Q4 24 | 33.9% | 41.4% | ||
| Q3 24 | 37.2% | 41.9% |
营业利润率PRGOSWKS
| Q2 26 | — | 4.5% | ||
| Q1 26 | — | 10.0% | ||
| Q4 25 | -116.0% | 10.1% | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 4.3% | 11.5% | ||
| Q1 25 | 4.5% | 10.2% | ||
| Q4 24 | 10.0% | 16.9% | ||
| Q3 24 | 7.4% | 5.8% |
净利率PRGOSWKS
| Q2 26 | — | 3.8% | ||
| Q1 26 | — | 7.6% | ||
| Q4 25 | -127.8% | 12.9% | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | -0.8% | 10.9% | ||
| Q1 25 | -0.6% | 7.2% | ||
| Q4 24 | -3.9% | 15.2% | ||
| Q3 24 | -1.9% | 5.9% |
每股收益（稀释后）PRGOSWKS
| Q2 26 | — | $0.24 | ||
| Q1 26 | — | $0.53 | ||
| Q4 25 | $-10.23 | $0.95 | ||
| Q3 25 | $0.05 | — | ||
| Q2 25 | $-0.06 | $0.70 | ||
| Q1 25 | $-0.05 | $0.43 | ||
| Q4 24 | $-0.32 | $1.00 | ||
| Q3 24 | $-0.15 | $0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $5.8B |
| 总资产 | $8.5B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGOSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | $432.1M | — | ||
| Q2 25 | $454.2M | $1.3B | ||
| Q1 25 | $409.9M | $1.5B | ||
| Q4 24 | $558.8M | $1.7B | ||
| Q3 24 | $1.5B | $1.6B |
总债务PRGOSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | $496.6M | ||
| Q4 25 | — | $496.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $496.2M | ||
| Q1 25 | — | $995.1M | ||
| Q4 24 | — | $994.7M | ||
| Q3 24 | — | $994.3M |
股东权益PRGOSWKS
| Q2 26 | — | $5.8B | ||
| Q1 26 | — | $5.8B | ||
| Q4 25 | $2.9B | $5.8B | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | $5.7B | ||
| Q1 25 | $4.4B | $5.9B | ||
| Q4 24 | $4.3B | $6.4B | ||
| Q3 24 | $4.6B | $6.3B |
总资产PRGOSWKS
| Q2 26 | — | $7.9B | ||
| Q1 26 | — | $7.9B | ||
| Q4 25 | $8.5B | $7.9B | ||
| Q3 25 | $10.1B | — | ||
| Q2 25 | $10.1B | $7.7B | ||
| Q1 25 | $9.8B | $7.9B | ||
| Q4 24 | $9.6B | $8.3B | ||
| Q3 24 | $11.2B | $8.3B |
负债/权益比PRGOSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | 0.09× | ||
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.09× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $50.3M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | 8.7% |
| 现金转化率经营现金流/净利润 | — | 1.41× |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGOSWKS
| Q2 26 | — | $50.3M | ||
| Q1 26 | — | $395.5M | ||
| Q4 25 | $175.4M | $200.0M | ||
| Q3 25 | $51.7M | — | ||
| Q2 25 | $75.9M | $314.2M | ||
| Q1 25 | $-64.5M | $409.4M | ||
| Q4 24 | $312.6M | $377.2M | ||
| Q3 24 | $42.2M | $476.1M |
自由现金流PRGOSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | $339.0M | ||
| Q4 25 | $148.6M | $144.0M | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | $252.7M | ||
| Q1 25 | $-90.0M | $370.9M | ||
| Q4 24 | $274.9M | $338.2M | ||
| Q3 24 | $15.1M | $393.3M |
自由现金流率PRGOSWKS
| Q2 26 | — | — | ||
| Q1 26 | — | 32.7% | ||
| Q4 25 | 13.4% | 13.1% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | 26.2% | ||
| Q1 25 | -8.6% | 38.9% | ||
| Q4 24 | 24.2% | 31.7% | ||
| Q3 24 | 1.4% | 38.4% |
资本支出强度PRGOSWKS
| Q2 26 | — | 8.7% | ||
| Q1 26 | — | 5.5% | ||
| Q4 25 | 2.4% | 5.1% | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | 6.4% | ||
| Q1 25 | 2.4% | 4.0% | ||
| Q4 24 | 3.3% | 3.6% | ||
| Q3 24 | 2.5% | 8.1% |
现金转化率PRGOSWKS
| Q2 26 | — | 1.41× | ||
| Q1 26 | — | 4.99× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | 2.99× | ||
| Q1 25 | — | 5.96× | ||
| Q4 24 | — | 2.33× | ||
| Q3 24 | — | 7.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
SWKS
暂无分部数据
